Inhibikase Therapeutics, Inc. financial statements
Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Inhibikase Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.7
3.1
0.12
0.26
0
Research and development
0.89
11.4
12
13.6
17.2
29.8
Selling, general and administrative
2.62
6.51
6.22
6.73
11.4
23.6
Operating income
-2.82
-14.8
-18.1
-20.1
-28.6
-52
Interest expense
0.03
0.02
Pre-tax income
-0.03
-0.05
Income tax
0
0
Net income
-2.85
-14.8
-18.1
-19
-27.5
-48.3
EBITDA
-14.8
-18.1
-19.9
-28.6
-51.9
EPS, basic
-1.84
-4.26
-3.79
-3.16
-1.16
-0.49
EPS, diluted
-1.84
-4.26
-3.79
-3.16
-1.16
-0.49
Shares, basic (weighted)
1.56
3.46
4.77
6.03
23.7
98.3
Shares, diluted (weighted)
1.56
3.46
4.77
6.03
23.7
98.3
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
14
40.8
7.19
9.2
97.5
179
Short-term investments
0
15.9
4.09
41.1
39.5
Other current assets
0.05
1.5
0.16
0.74
0.83
0.34
Total current assets
14.8
42.5
24.4
14.2
98.5
180
Property, plant and equipment
0
0.24
0.07
0.05
0
Lease right-of-use assets
0
0.33
0.22
0.1
0
Other non-current assets
0
0.1
Total assets
14.8
42.5
24.9
14.5
98.6
181
Accounts payable
1.72
1.09
1.15
0.65
0.94
1.16
Accrued liabilities
0.63
2.72
2.4
2.26
2.68
4.08
Deferred revenue
2.33
0
Short-term debt
0
0.15
0.15
0.11
0
Total current liabilities
4.72
4.05
3.7
3.44
3.73
8.3
Long-term debt
0.28
0
Lease liabilities
0.21
0.09
Total liabilities
5
4.05
3.9
3.53
3.73
8.3
Total debt
0.25
0.15
0.38
0.11
0
Paid-in capital
24.8
68.2
68.8
77.9
189
315
Retained earnings
15
-29.8
-47.9
-66.9
-94.4
-143
Other comprehensive income
0
0.1
0
-0.04
0.02
Shareholders' equity
9.78
38.4
21
11
94.9
173
Total equity
9.78
38.4
21
11
94.9
173
Total liabilities and equity
14.8
42.5
24.9
14.5
98.6
181
Shares outstanding
1.91
4.78
4.77
6.19
69.4
132
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-2.85
-14.8
-18.1
-19
-27.5
-48.3
Depreciation and amortization
0
0.01
0.18
0.03
0.06
Stock-based compensation
0.57
1.53
0.46
0.5
8.14
15.3
Change in receivables
0
-0.11
-0.04
0.04
0
Change in payables
-0.25
-0.63
0.06
-0.5
0.27
0.15
Cash from operations
-1.13
-14.3
-17.4
-18.1
-19.1
-27.8
Capital expenditures
0
-0.24
-0.01
0
-0.01
Purchases of investments
0
-20.7
-29.4
-60.5
-39.1
Sales and maturities of investments
4.96
41.1
23.5
41.6
Cash from investing
0
-16
11.7
-37
2.05
Stock issued
0
0
0
8.54
103
108
Cash from financing
15.1
41.1
-0.2
8.41
103
108
Net change in cash
13.9
26.8
-33.6
1.98
47.3
82.7
Free cash flow
-14.3
-17.6
-18.1
-19.1
-27.8
Interest paid
0.01
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $2.06 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-39.5%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-37.1%
Net income / average total assets.
Return on invested capital (ROIC)
-42.3%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
82.3%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
101.8%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
77.6%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
83.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
93.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
65.1%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
314.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
174.2%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
129.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
15.8x
Current assets / current liabilities.
Quick ratio
15.5x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
15.5x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$0.24
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.24
Cash from operations / diluted weighted shares.
Book value per share
$1.16
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.87x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.87x
Market cap / tangible book value, when positive.
FCF yield
-14.8%
Free cash flow / market cap.
Earnings yield
-21.1%
Net income / market cap (the inverse of P/E).
Was Inhibikase Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $48.3M.
How much free cash flow did Inhibikase Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $27.8M minus capital expenditures of $13.4K left free cash flow of -$27.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.